^“Confirmation of the mapping of the Camurati-Englemann locus to 19q13. 2 and refinement to a 3.2-cM region”. Genomics66 (1): 119–21. (May 2000). doi:10.1006/geno.2000.6192. PMID10843814.
^“Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization”. J. Biol. Chem.258 (11): 7155–60. (1983). doi:10.1016/S0021-9258(18)32345-7. PMID6602130.
^“Transforming growth factor-beta is a potent immunosuppressive agent that inhibits IL-1-dependent lymphocyte proliferation”. J. Immunol.140 (9): 3026–32. (1988). doi:10.4049/jimmunol.140.9.3026. PMID3129508.
^“Transforming growth factor-beta inhibits human antigen-specific CD4+ T cell proliferation without modulating the cytokine response”. Int. Immunol.15 (12): 1495–504. (2003). doi:10.1093/intimm/dxg147. PMID14645158.
^“Transforming growth factor-beta 1 induces antigen-specific unresponsiveness in naive T cells”. Immunol. Invest.26 (4): 459–72. (1997). doi:10.3109/08820139709022702. PMID9246566.
^“Role and mechanisms of cytokines in the secondary brain injury after intracerebral hemorrhage”. Prog. Neurobiol.178: 101610. (March 2019). doi:10.1016/j.pneurobio.2019.03.003. PMID30923023.
^“Human myeloid dendritic cells treated with supernatants of rotavirus infected Caco-2 cells induce a poor Th1 response”. Cellular Immunology272 (2): 154–61. (2012-01-01). doi:10.1016/j.cellimm.2011.10.017. PMID22082567.
^“The Smad3 protein is involved in TGF-beta inhibition of class II transactivator and class II MHC expression”. Journal of Immunology167 (1): 311–9. (July 2001). doi:10.4049/jimmunol.167.1.311. PMID11418665.
^“Decorin core protein fragment Leu155-Val260 interacts with TGF-beta but does not compete for decorin binding to type I collagen”. Arch. Biochem. Biophys.355 (2): 241–8. (July 1998). doi:10.1006/abbi.1998.0720. PMID9675033.
^“Bone matrix decorin binds transforming growth factor-beta and enhances its bioactivity”. J. Biol. Chem.269 (51): 32634–8. (Dec 1994). doi:10.1016/S0021-9258(18)31681-8. PMID7798269.
^“The type II transforming growth factor (TGF)-beta receptor-interacting protein TRIP-1 acts as a modulator of the TGF-beta response”. J. Biol. Chem.273 (47): 31455–62. (November 1998). doi:10.1074/jbc.273.47.31455. PMID9813058.
“Latent transforming growth factor-beta: structural features and mechanisms of activation”. Kidney Int.51 (5): 1376–82. (1997). doi:10.1038/ki.1997.188. PMID9150447.
“The biology of the small leucine-rich proteoglycans. Functional network of interactive proteins”. J. Biol. Chem.274 (27): 18843–6. (1999). doi:10.1074/jbc.274.27.18843. PMID10383378.
“Association of polymorphisms of the transforming growth factor-beta1 gene with genetic susceptibility to osteoporosis”. Pharmacogenetics11 (9): 765–71. (2001). doi:10.1097/00008571-200112000-00004. PMID11740340.
“TGF-β: Receptors, Signaling Pathways and Autoimmunity”. TGF-beta: receptors, signaling pathways and autoimmunity. Current Directions in Autoimmunity. 5. (2002). 62–91. doi:10.1159/000060548. ISBN978-3-8055-7308-5. PMID11826761
“Survival and cell cycle control in early hematopoiesis: role of bcl-2, and the cyclin dependent kinase inhibitors P27 and P21”. Leuk. Lymphoma43 (1): 51–7. (2002). doi:10.1080/10428190210195. PMID11908736.
“Transforming growth factor beta and atherosclerosis: so far, so good for the protective cytokine hypothesis”. Arterioscler. Thromb. Vasc. Biol.24 (3): 399–404. (2004). doi:10.1161/01.ATV.0000114567.76772.33. PMID14699019.
“Transforming growth factor-beta: a clinical target for the treatment of diabetic nephropathy”. Curr. Diab. Rep.4 (6): 447–54. (2004). doi:10.1007/s11892-004-0055-z. PMID15539010.
“Integrin-mediated activation of latent transforming growth factor beta”. Cancer Metastasis Rev.24 (3): 395–402. (2005). doi:10.1007/s10555-005-5131-6. PMID16258727.